BENSALEM, Pa., Jan. 14, 2025 /PRNewswire/ -- The Law Offices of Howard G. Smith announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against Applied Therapeutics, Inc. ("Applied Therapeutics" or the "Company") (NASDAQ: APLT).IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN APPLIED THERAPEUTICS, INC. (APLT), CONTACT THE LAW OFFICES OF HOWARD G. SMITH BEFORE FEBRUARY 18, 2025 (LEAD PLAINTIFF DEADLINE) TO PARTICIPATE IN THE ONGOING SECURITIES FRAUD LA ...

NEW YORK, Jan. 14, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Applied Therapeutics, Inc. ("Applied Therapeutics" or the "Company") (NASDAQ: APLT) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Applied Therapeutics investors who were adversely affected by alleged securities fraud between January 3, 2024 and December 2, 2024. Follow the link below to get more information and be contacted by a member of our team:https://zlk.com/pslr ...

Core Viewpoint - The article discusses a class action lawsuit against Applied Therapeutics, Inc. for alleged violations of the Securities Exchange Act of 1934, focusing on misleading statements and failure to adhere to clinical trial protocols, which led to significant stock price declines following negative FDA responses [1][3][4]. Company Overview - Applied Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing novel drug candidates for rare diseases, specifically targeting validated molecular pathways [2]. Legal Allegations - The class action lawsuit alleges that during the class period from January 3, 2024, to December 2, 2024, Applied Therapeutics and its executives made false or misleading statements regarding the company's adherence to trial protocols, which posed a risk of FDA rejection of their New Drug Application (NDA) for govorestat [3][4]. - On November 27, 2024, it was revealed that the FDA issued a Complete Response Letter for the NDA, indicating that the application could not be approved in its current form due to clinical application deficiencies, resulting in an over 80% stock price drop over three trading sessions [4]. - On December 2, 2024, Applied Therapeutics disclosed receiving a warning from the FDA regarding issues with electronic data capture and a dosing error, leading to a further decline of more than 26% in stock price over three trading sessions [5]. Class Action Process - The Private Securities Litigation Reform Act of 1995 allows investors who purchased Applied Therapeutics securities during the class period to seek appointment as lead plaintiff in the lawsuit, representing the interests of all class members [6]. Law Firm Background - Robbins Geller Rudman & Dowd LLP is a leading law firm specializing in securities fraud cases, having secured over $6.6 billion for investors in class action cases, and is recognized for obtaining significant recoveries in securities litigation [7].

NEW YORK, Jan. 13, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Applied Therapeutics, Inc. ("Applied Therapeutics" or the "Company") (NASDAQ: APLT) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Applied Therapeutics investors who were adversely affected by alleged securities fraud between January 3, 2024 and December 2, 2024. Follow the link below to get more information and be contacted by a member of our team: https://zlk.co ...

RADNOR, Pa., Jan. 11, 2025 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed in the United States District Court for the Southern District of New York against Applied Therapeutics, Inc. ("Applied Therapeutics") (NASDAQ: APLT) on behalf of those who purchased or otherwise acquired Applied Therapeutics securities between January 3, 2024, and December 2, 2024, inclusive (the "Class Period"). The lead plainti ...

Class Action Lawsuit - Levi & Korsinsky, LLP notifies investors in Applied Therapeutics, Inc (NASDAQ: APLT) of a class action securities lawsuit seeking to recover losses for investors affected by alleged securities fraud between January 3, 2024 and December 2, 2024 [1] Case Details - Applied Therapeutics received a Complete Response Letter (CRL) from the FDA on November 27, 2024 for its New Drug Application (NDA) for govorestat, citing deficiencies in the clinical application [2] - Following the CRL announcement, Applied Therapeutics' stock price declined from $10 21 per share on November 26, 2024 to $8 57 per share on November 27, 2024, and further to $2 03 on November 29, 2024 and $1 75 per share on December 2, 2024, a total decline of more than 80% [2] - On December 2, 2024, Applied Therapeutics disclosed a "warning letter" from the FDA regarding clinical trial issues, causing the stock price to fall further to $1 69 per share on December 3, 2024, $1 38 per share on December 4, 2024, and $1 29 per share on December 5, 2024 [2] Next Steps for Investors - Investors who suffered losses in Applied Therapeutics during the relevant time frame have until February 18, 2025 to request the Court appoint them as lead plaintiff [3] - Class members may be entitled to compensation without payment of any out-of-pocket costs or fees [3] Levi & Korsinsky Expertise - Levi & Korsinsky has secured hundreds of millions of dollars for aggrieved shareholders over the past 20 years and has a team of over 70 employees [4] - The firm has ranked in ISS Securities Class Action Services' Top 50 Report as one of the top securities litigation firms in the United States for seven consecutive years [4]

NEW YORK, Jan. 7, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Applied Therapeutics, Inc. ("Applied Therapeutics" or the "Company") (NASDAQ: APLT) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Applied Therapeutics investors who were adversely affected by alleged securities fraud between January 3, 2024 and December 2, 2024. Follow the link below to get more information and be contacted by a member of our team:https://zlk.com/pslra ...

NEW YORK, Jan. 6, 2025 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Applied Therapeutics, Inc. (NASDAQ: APLT) between January 3, 2024 and December 2, 2024, both dates inclusive (the "Class Period"), of the important February 18, 2025 lead plaintiff deadline.So what: If you purchased Applied Therapeutics securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee a ...

Class Action Lawsuit Overview - The law firm Robbins Geller Rudman & Dowd LLP announced a class action lawsuit against Applied Therapeutics Inc (NASDAQ: APLT) for securities purchased or acquired between January 3 2024 and December 2 2024 [1] - The lawsuit alleges violations of the Securities Exchange Act of 1934 by Applied Therapeutics and certain top executives [1] - Investors who suffered substantial losses can seek appointment as lead plaintiff by February 18 2025 [1] Case Allegations - Applied Therapeutics is a clinical-stage biopharmaceutical company developing drug candidates for rare diseases [2] - The company submitted a New Drug Application (NDA) to the FDA for govorestat to treat Classic Galactosemia on January 3 2024 [2] - The lawsuit claims that Applied Therapeutics made false or misleading statements and failed to disclose non-adherence to trial protocols and good clinical practices, risking FDA rejection of trial data [3] FDA Response and Stock Impact - On November 27 2024, the FDA issued a Complete Response Letter for the NDA, stating it could not approve the application in its current form due to deficiencies in the clinical application [4] - Following this news, Applied Therapeutics stock price fell more than 80% over three trading sessions [4] - On December 2 2024, the company disclosed an FDA warning regarding issues with electronic data capture and a dosing error in the study, leading to a further 26% drop in stock price over three trading sessions [5] Lead Plaintiff Process - Investors who purchased or acquired Applied Therapeutics securities during the Class Period can seek appointment as lead plaintiff under the Private Securities Litigation Reform Act of 1995 [6] - The lead plaintiff represents all class members and selects the law firm to litigate the case [6] - Serving as lead plaintiff is not required to share in any potential future recovery [6] About Robbins Geller - Robbins Geller Rudman & Dowd LLP is a leading law firm in securities fraud cases, ranked 1 in ISS Securities Class Action Services for six of the last ten years [7] - The firm has recovered $6 6 billion for investors in securities-related class action cases, including the largest recovery ever of $7 2 billion in the Enron Corp case [7]

NEW YORK, Jan. 6, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Applied Therapeutics, Inc. (NASDAQ: APLT).Shareholders who purchased shares of APLT during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/applied-therapeutics-inc-loss-submission-form/?id=120460&from=4 CLASS PERIOD: J ...